UNSPSC 51151529: Rivastigmine

This classification denotes an acetylcholinesterase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PKI06M3IW0. European Medicines Agency schedules Rivastigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10345MIG. Rivastigmine generally arises in the molecular formula C14H22N2O2.

UNSPSC 51151529 Rivastigmine, a Commodity code, nominally covers a single pharmaceutical product — an Alzheimer's disease medication — yet the recent state and local opportunities tagged under it do not reflect this specific drug. Instead, the code shows activity focused on naloxone procurement and exploratory pharmacy benefit management programs. State and local governments are using this code to solicit naloxone (opioid antagonist) supplies and to gather market intelligence on direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments and state health and human services agencies. The mismatch between the code's nominal scope and actual procurement activity suggests either a tagging error in the source data or a broader interpretation of the code by procuring jurisdictions that extends beyond rivastigmine itself to related pharmaceutical and pharmacy-management services.

Seminole County, Florida posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source), with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, to solicit vendor capabilities regarding direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and group purchasing organizations. Neither opportunity directly concerns rivastigmine procurement, and the code shows limited recent activity aligned with its nominal pharmaceutical scope. Vendors evaluating this code should note the geographic concentration in Florida and Texas and the shift toward naloxone, opioid-response products, and pharmacy benefit restructuring as the actual work being solicited under this tagged code.